Literature DB >> 9093956

Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial.

P A Cleary1, R W Beck, L B Bourque, J C Backlund, P H Miskala.   

Abstract

As part of the Optic Neuritis Treatment Trial, vision-specific quality-of-life data were collected on the patients at their 6-month visits. The purpose of this study was to determine the types of visual tasks in day-to-day living in which patients have difficulty and to compare the patients' subjective assessment of visual impairment with measurements of visual acuity, contrast sensitivity, mean deviation, and color vision. The questionnaire was completed by 382 (87%) of the 438 patients who had 6-month study visits. Associations between ophthalmic test scores and self-reported vision were examined using both a summary problem index and selected individual items. Although a substantial percentage of the patients (63%) indicated that vision had not recovered to normal in the affected eye, the reported visual deficits generally were mild. For most of the visual tasks of daily living, patients reported little or no problem. Among the 215 patients who perceived their vision at 6 months to be somewhat or much worse than it was before optic neuritis, 20% had normal results on none of the four visual function tests, 14% had normal results on one of the four tests, 23% had two of four, 23% had three of four, and 20% had normal results on all four. Reported visual symptoms 6 months after optic neuritis generally were mild. When patients were symptomatic, the four visual function tests often did not detect abnormality. This finding supports previous reports that visual deficits are frequently perceived even when vision testing is normal.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9093956     DOI: 10.1016/s0002-9394(14)70814-1

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  19 in total

Review 1.  Corticosteroids for treating optic neuritis.

Authors:  Robin L Gal; Satyanarayana S Vedula; Roy Beck
Journal:  Cochrane Database Syst Rev       Date:  2015-08-14

2.  New developments in the treatment of optic neuritis.

Authors:  Thomas M Jenkins; Ahmed T Toosy
Journal:  Eye Brain       Date:  2010-06-17

3.  How Common Is Signal-Intensity Increase in Optic Nerve Segments on 3D Double Inversion Recovery Sequences in Visually Asymptomatic Patients with Multiple Sclerosis?

Authors:  T Sartoretti; E Sartoretti; S Rauch; C Binkert; M Wyss; D Czell; S Sartoretti-Schefer
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-29       Impact factor: 3.825

4.  Approach to the patient with acute monocular visual loss.

Authors:  Sashank Prasad; Steven L Galetta
Journal:  Neurol Clin Pract       Date:  2012-03

5.  Assessing visual pathway function in multiple sclerosis patients with multifocal visual evoked potentials.

Authors:  Michal Laron; Han Cheng; Bin Zhang; Jade S Schiffman; Rosa A Tang; Laura J Frishman
Journal:  Mult Scler       Date:  2009-12-07       Impact factor: 6.312

Review 6.  A Comparison of Optic Neuritis in Asian and in Western Countries.

Authors:  Lin-Chung Woung; Hui-Chuan Chung; Jieh-Ren Jou; Kai-Chen Wang; Pai-Huei Peng
Journal:  Neuroophthalmology       Date:  2011-03-20

7.  Validity and reliability study of Turkish version on low vision with quality of life questionnaire.

Authors:  Aysun Idil; Mehmet Ozen; Nazli Atak; Atilla Elhan; Selcen Pehlivan
Journal:  Int J Ophthalmol       Date:  2011-10-18       Impact factor: 1.779

8.  Focal macular photopic negative response in patients with optic neuritis.

Authors:  H Nakamura; K Miyamoto; S Yokota; K Ogino; N Yoshimura
Journal:  Eye (Lond)       Date:  2011-01-07       Impact factor: 3.775

9.  Implementation methods for vision related quality of life questionnaires.

Authors:  J S Wolffsohn; A L Cochrane; N A Watt
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

10.  Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.

Authors:  Lindsay Horton; Amy Conger; Darrel Conger; Gina Remington; Teresa Frohman; Elliot Frohman; Benjamin Greenberg
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.